Last reviewed · How we verify

Refractory Aspergillosis — Treatment Landscape & Competitive Intelligence

Refractory Aspergillosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Refractory Aspergillosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cancidas CASPOFUNGIN Merck & Co. Echinocandin Antifungal ATP-binding cassette sub-family G member 2 2001-01-01
Abelcet AMPHOTERICIN B Astellas Pharma Lipid-based Polyene Antifungal [EPC] 1964-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Astellas Pharma · 1 drug in Refractory Aspergillosis
  2. Merck & Co. · 1 drug in Refractory Aspergillosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Refractory Aspergillosis:

Cite this brief

Drug Landscape (2026). Refractory Aspergillosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/refractory-aspergillosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing